Abraham C.F. Leung
Research Subjects
Abraham C.F. Leung has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Emiliano Calvo
START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Madrid, Spain
46 shared publications - Funda Meric-Bernstam
Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, USA
46 shared publications - Giuseppe Curigliano
Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
46 shared publications - Victor Moreno
START Madrid-FJD, Early Phase Clinical Trials Unit, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
46 shared publications - Yeon Hee Park
Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
46 shared publications - Keun Seok Lee
Center for Breast Cancer, National Cancer Center, Goyang, Republic of Korea
45 shared publications
Latest Publications
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Safety and Tolerability of a Novel Anti-HER2 Antibody–Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study
Supplementary Table S4 shows the immunogenicity results
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Safety and Tolerability of a Novel Anti-HER2 Antibody–Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study
Supplementary Table S4 shows the immunogenicity results
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Safety and Tolerability of a Novel Anti-HER2 Antibody–Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study
Supplementary Table S1 shows the treatment-related adverse events
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Safety and Tolerability of a Novel Anti-HER2 Antibody–Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study
Supplementary Table S1 shows the treatment-related adverse events
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Safety and Tolerability of a Novel Anti-HER2 Antibody–Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study
Supplementary Table S2 shows the PK results
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Safety and Tolerability of a Novel Anti-HER2 Antibody–Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study
Supplementary Table S2 shows the PK results
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Safety and Tolerability of a Novel Anti-HER2 Antibody–Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study
Supplementary Figure S3 shows the time to and duration of response in patients with confirmed CR or PR (the mITT population)
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Safety and Tolerability of a Novel Anti-HER2 Antibody–Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study
Supplementary Figure S3 shows the time to and duration of response in patients with confirmed CR or PR (the mITT population)
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Safety and Tolerability of a Novel Anti-HER2 Antibody–Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study
Supplementary Table S3 shows the biomarker results
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Safety and Tolerability of a Novel Anti-HER2 Antibody–Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study
Supplementary Table S3 shows the biomarker results
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary File 1 from Safety and Tolerability of a Novel Anti-HER2 Antibody–Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study
Supplementary File 1 shows the Methods and Results for Part 1B
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary File 1 from Safety and Tolerability of a Novel Anti-HER2 Antibody–Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study
Supplementary File 1 shows the Methods and Results for Part 1B
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Safety and Tolerability of a Novel Anti-HER2 Antibody–Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study
Supplementary Figure S2 shows the duration of treatment including response and tumor type (the safety analysis set)
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Safety and Tolerability of a Novel Anti-HER2 Antibody–Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study
Supplementary Figure S2 shows the duration of treatment including response and tumor type (the safety analysis set)
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Safety and Tolerability of a Novel Anti-HER2 Antibody–Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study
Supplementary Figure S1 shows the study design.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Safety and Tolerability of a Novel Anti-HER2 Antibody–Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study
Supplementary Figure S1 shows the study design.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Safety and Tolerability of a Novel Anti-HER2 Antibody-Drug Conjugate (PF-06804103) in Patients With HER2-Expressing Solid Tumors: A Phase 1 Dose Escalation Study
Supplementary Table S1 shows the treatment-related adverse events
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Safety and Tolerability of a Novel Anti-HER2 Antibody-Drug Conjugate (PF-06804103) in Patients With HER2-Expressing Solid Tumors: A Phase 1 Dose Escalation Study
Supplementary Table S1 shows the treatment-related adverse events
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Safety and Tolerability of a Novel Anti-HER2 Antibody-Drug Conjugate (PF-06804103) in Patients With HER2-Expressing Solid Tumors: A Phase 1 Dose Escalation Study
Supplementary Figure S2 shows the duration of treatment including response and tumor type (the safety analysis set)
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Safety and Tolerability of a Novel Anti-HER2 Antibody-Drug Conjugate (PF-06804103) in Patients With HER2-Expressing Solid Tumors: A Phase 1 Dose Escalation Study
Supplementary Figure S2 shows the duration of treatment including response and tumor type (the safety analysis set)